Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells
about
RAIN-Droplet: a novel 3D in vitro angiogenesis modelThe combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenibMultiple mechanisms mediate resistance to sorafenib in urothelial cancerInhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancerSafety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signalingTargeting the VEGF pathway in metastatic bladder cancer.Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells.Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment.Imaging-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model.Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.
P2860
Q30579854-DE43D3BA-E354-4C43-82ED-361FE48CEDBCQ33977116-67D12E6F-5A42-4B6D-A19F-E15F3F15944BQ34685436-73C5756B-92F9-445F-92FB-BE11565EE926Q35040383-3EECA842-B9C5-47A3-9E5D-01B1646E8091Q35998718-023D8874-5958-4002-8A91-A0A86961BB27Q36639895-B25162DC-2388-4B24-91C8-819D58F799D3Q36919811-172AA2AB-1B35-41B1-B6C4-D4F3656D89BDQ38534167-E3EDF195-C0C9-4A9F-AFD9-5C70BB99EFF6Q38969661-5DE56658-8437-47EE-BF98-D8CA91E67252Q38996046-7D37F711-5855-4059-BAC1-BFAB053DD4D5Q41770394-DCE1953C-E597-439B-938C-6AE65578E717Q43718098-D4369803-CB29-430C-9DFF-38F593E001B0Q45901060-A451C338-DDB9-4234-B777-2337804F3DE3Q50113746-EA48924B-6E13-46C4-AA1D-AB1D4AA38EDDQ51098298-648D8BEC-84D3-48B9-B1AE-A9FD51642519
P2860
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells
@en
Stimulatory effects of the mul ...... on human bladder cancer cells.
@nl
type
label
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells
@en
Stimulatory effects of the mul ...... on human bladder cancer cells.
@nl
prefLabel
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells
@en
Stimulatory effects of the mul ...... on human bladder cancer cells.
@nl
P2093
P2860
P1476
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells
@en
P2093
A Rosenkranz
F vom Dorp
J W Fischer
M Grandoch
P2860
P304
P356
10.1111/J.1476-5381.2010.00838.X
P407
P577
2010-08-01T00:00:00Z